Kiromic BioPharma, Inc.
KRBPQ
$0.00
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.16M | 9.53M | 10.01M | 10.10M | 10.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.77M | 23.39M | 22.34M | 20.28M | 19.94M |
| Operating Income | -23.77M | -23.39M | -22.34M | -20.28M | -19.94M |
| Income Before Tax | -26.90M | -25.10M | -21.86M | -21.80M | -20.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.90 | -25.10 | -21.86 | -21.80 | -20.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.90M | -25.10M | -21.86M | -21.80M | -20.95M |
| EBIT | -23.77M | -23.39M | -22.34M | -20.28M | -19.94M |
| EBITDA | -21.54M | -21.17M | -20.11M | -18.05M | -17.72M |
| EPS Basic | -3.98 | -13.95 | -12.11 | -13.56 | -14.26 |
| Normalized Basic EPS | -11.41 | -11.09 | -10.31 | -11.49 | -12.34 |
| EPS Diluted | -3.98 | -13.95 | -12.11 | -13.56 | -14.26 |
| Normalized Diluted EPS | -11.41 | -11.09 | -10.31 | -11.49 | -12.34 |
| Average Basic Shares Outstanding | 5.90M | 5.63M | 5.27M | 4.82M | 4.39M |
| Average Diluted Shares Outstanding | 5.90M | 5.63M | 5.27M | 4.82M | 4.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |